Pharmaceutical Industry Today

Global Biological Drugs Market to reach $287 billion by 2020 owing to Rising Incidence of Chronic Diseases by PMR

North America dominates the global biological drugs market. This is due to increasing use of biological drugs in the treatment of diseases such as cancer, diabetes, and other chronic diseases in the region.
Published 05 August 2015

New York: According to the latest market research report released by Persistence Market Research, the global biological drugs market,which in 2014 stood at US$161056.5 million is anticipated to expand at a CAGR of 10.1% between 2014 and 2020, thereby reaching a market value of US$287139.7 million by 2020. The report titled “Global Market Study on Biological Drugs: North America to Witness Highest Growth By 2020” is available for sale on the company website.

View Full Report TOC: http://www.persistencemarketresearch.com/market-research/global-biological-drugs-market.asp

A growing geriatric population, rising incidence of chronic ailments, and greater initiatives by government bodies are a few of the key factors that propel the global biological drugs market. The structure of biological drugs is quite complex when compared to the regular conventional drugs. Biological drugs are used in treating and preventing diseases such as auto-immune diseases, cancer, and blood disorders amongst other ailments. The manufacturing process of biological drugs involves close to 250 in-process tests as against the manufacturing of conventional drugs which involves only 50 tests.

This PMR report explains that apart from the aforementioned market drivers, the other factors that stimulate the demand for biological drugs are advancements in and greater R&D in the field of medical sciences, and an increasing number of government bodies promoting the use of biological drugs for treating ailments and diseases.

The global biological drugs market on the basis of monoclonal antibodies, a therapeutic protein, vaccine, and geography. The patent expiration of popular drugs and high costs of biological drugs are some of the challenges faced by the global biological drugs market. The growth of this market is also hampered by the potential risks associated with the adverse impacts of injectable biological drugs.

Request Report Sample: http://www.persistencemarketresearch.com/samples/2883

The global biological drugs market is segmented into four key regions: North America, Asia Pacific, Europe, and Rest of the World. Owing to widespread consumption of biological drugs for treating diseases such as diabetes and cancer, North America holds the highest share in the global biological drugs market. The North America market is also characterized by government institutions supporting the consumption of biological drugs. The Europe biological drugs market mainly driven by high demand for the same from the growing geriatric population in this region.

As per a latest UN report, the geriatric population in Germany will increase from 23.2% of the total population in 2000 to 33.2% of the total population by 2025. The effectiveness of biological drugs is being observed in the treatment of age-related medical conditions such as glaucoma and macular degeneration. Asia is proving to be a very lucrative investment destinations for companies operating in the global biological drugs market. Lonza is one such biotechnology firm based in Switzerland that has invested funds worth US$350 million in India and Singapore. Such a step is aimed at enhancing activities in the biological drugs markets in these regions.

Some of the prominent companies in the global biological drugs market, identified in the report are Baxter International Inc., Abbott Laboratories, GlaxoSmithKline plc, Merck & Co, Inc., Biogen Idec., Novartis AG, and Pfizer Inc.

The global biological drugs market is segmented as follows:
 
By therapeutic protein
  • Enbrel
  • Lantus
  • Neulasta
  • Avonex
  • NovoLog
  • Rebif
  • Humalog
  • Aranesp
  • Epogen
  • Levemir
  • Victoza
  • Betaseron
  • Neupogen
  • Eylea
By monoclonal antibody (mAb)
  • Humira
  • Remicade
  • Rituxan
  • Avastin
  • Herceptin
  • Lucentis
By vaccine
  • Prenvar 13
  • Gardasil
  • Fluzone
  • Varivax
  • Cervarix
By geography
  • North America
  • Europe
  • Asia
  • Rest of the World (RoW)

About Us

Persistence Market Research (PMR) is a market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and a high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.

Contact
Persistence Market Research
305 Broadway
7th Floor
New York City, NY 10007
United States
USA-Canada Toll-Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com

Other Industry News

Ready to start publishing

Sign Up today!